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Abstract
The binding of antibodies to the CD4-binding site (CD4bs) of the HIV-1 envelope glycoprotein gp120 has been shown to induce gp120 to
undergo conformational changes that can expose and/or shield specific epitopes on gp120. Here, we study alterations in the antigenicity and
immunogenicity of gp120 when complexed with human monoclonal antibodies (mAbs) specific for the CD4bs of gp120. The data showed that
gp120 bound by anti-CD4bs mAbs had enhanced reactivity with mAbs to the V3 and N-terminal regions, but not with mAb to the C terminus.
Moreover, mice immunized with the gp120/anti-CD4bs mAb complexes produced higher titers of gp120-specific serum IgG and IgA than mice
immunized with uncomplexed gp120 or other gp120/mAb complexes. Notably, the enhanced antibody production was directed against V3 and
correlated with better exposure of V3 on the gp120/anti-CD4bs mAb complexes. The higher antibody reactivity was evident against the
homologous V3LAI peptide, but not against heterologous V3 peptides. Potent neutralization activity against HIV-1LAI was also observed in the sera
from mice immunized with gp120/anti-CD4bs mAb complexes, although the sera exhibited poor neutralizing activities against other viruses
tested. These results indicate that the anti-CD4bs antibodies alter the antigenicity and immunogenicity of gp120, leading to enhanced production
of anti-gp120 antibodies directed particularly against the V3 region.
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The capacity of immune complexes to augment antibody
(Ab) responses in an antigen-specific manner is well docu-
mented. Immune complexes are deposited and retained on
follicular dendritic cells in the lymphoid follicles, inducing B
cell activation and Ab production (Heyman, 2000). Indeed,
immune complexes have been tested as vaccines to augment Ab
responses to hepatitis B surface antigen (McCluskie et al., 1998;
Wen et al., 1999), infectious bursal disease virus (Ivan et al.,
2005; Kumar, 2001) as well as to equine herpesvirus 1 and
porcine parvovirus (Alber et al., 2000; Roic et al., 2006).
Additionally, Abs can affect the stability and conformation of
antigens, while shielding or exposing specific antigenic sites⁎ Corresponding author. 423 E. 23rd St. Room 18-124 North, New York, NY
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doi:10.1016/j.virol.2007.10.044(Jemmerson and Paterson, 1986). Previous studies with model
antigens such as dinitrophenylated keyhole limpet hemocyanin,
gamma globulin, and albumin have shown that immunization
with antigen–antibody complexes results in qualitatively and
quantitatively different Ab responses than with antigens alone
(Heyman, 2000). Subsequently, immunization with hepatitis B
surface antigen and Streptococcus mutans adhesin P1 bound by
different mAbs was found to elicit distinct specificities of serum
Abs, indicating the capacity of mAbs to redirect Ab responses
(Bouige et al., 1996; Brady et al., 2000; Oli et al., 2004). The
use of immune complexes has also been considered as a strategy
to augment Ab responses to the HIV-1 envelope glycoprotein
gp120 and especially to direct Abs toward critical neutralizing
epitopes on this viral surface antigen. However, an earlier effort
to immunize animals using HIV-1 envelope glycoprotein gp120
antigen complexed with mAb A32, which specifically induces
the mAb binding to the chemokine-receptor binding site, did not
enhance the production of cross-reactive neutralizing Abs
against this conserved region on gp120 (Liao et al., 2004).
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the CD4-binding site (CD4bs) of gp120 to alter the antigenicity
and immunogenicity of gp120. Anti-CD4bs Abs have broad
binding activity for gp120 of various HIV-1 subtypes due to the
highly conserved structure and function of the receptor-binding
site (Moore et al., 1994). Extensive mutagenesis analyses have
mapped the binding sites of different anti-CD4bs monoclonal
antibodies (mAbs) and revealed that the footprint of these mAbs
encompasses both the inner and outer domains of gp120,
indicating that similar to CD4, anti-CD4bs mAbs bring together
these two domains (Pantophlet et al., 2003; Thali et al., 1992;
Xiang et al., 2002). Thermodynamic studies have also shown
that the interaction of gp120 with anti-CD4bs mAbs induces
significant conformational changes involving the rearrangement
of the inner and outer domains (Kwong et al., 2002). The
crystallographic structure of the gp120/anti-CD4bs mAb b12
complex and the structural modeling of anti-CD4bs mAb F105
further confirm the construction of the mAb binding sites from
the two gp120 domains (Wilkinson et al., 2005; Zhou et al.,
2007). Moreover, the binding of anti-CD4bs mAbs to gp120 has
been shown to enhance the reactivity of anti-V3 mAbs (Pinter
et al., 1993), while at the same time, these mAbs block gp120
binding to the chemokine receptor (Raja et al., 2003), indicating
that these mAbs trigger specific structural changes, albeit not
necessarily the same as the CD4-induced bridging sheet re-
arrangement required for the chemokine receptor-binding site
(Zhou et al., 2007). Hence, we postulate that because the
binding of anti-CD4bs mAbs to gp120 changes antigenic prop-
erties of gp120, such that some regions of gp120 are better
exposed while others are hidden or modified, the use of immune
complexes made of gp120 and mAbs as immunogens should
alter and direct the Ab responses to specific regions of the
gp120 antigen.
To test this hypothesis, we probed the reactivity of gp120/
anti-CD4bs mAb complexes using mAbs specific for different
regions of gp120. Subsequently, we evaluated the levels and
specificities of anti-gp120 Ab responses induced in mice im-
munized with gp120/anti-CD4bs mAb complexes as compared
to immunization with uncomplexed gp120 or other gp120/mAb
complexes. Our data indicate that the binding of anti-CD4bs
mAb to gp120 enhances the exposure of the N-terminal C1
region and neutralizing epitopes in the V3 loop. Importantly,
immunization with gp120/anti-CD4bs mAb complexes consis-
tently elicits higher levels of serum anti-gp120 Abs directed
especially to the V3 region. Sera from the immunized mice also
exhibit much more potent virus-neutralizing activity than sera
of mice receiving uncomplexed gp120, although the neutraliz-
ing activity was observed primarily against the homologous
HIV-1 strain.
Results
The binding of anti-CD4bs mAbs to gp120 enhances exposure
of the V3 and C1 regions of gp120
Previous studies have reported that CD4 binding to gp120
can increase accessibility of the V3 loop to proteases as well asto anti-V3 mAbs (Mbah et al., 2001; Sattentau and Moore,
1991; Sattentau et al., 1993). To assess if the binding of anti-
CD4bs mAbs to gp120 could also induce structural changes that
increase the exposure of specific Ab epitopes on gp120, we
tested the reactivity of different biotinylated mAbs with the
gp120/anti-CD4bs mAb complex (gp120+654D) as compared
to the gp120/anti-C2 mAb complex (gp120+1006-30D), un-
complexed gp120 mixed with an irrelevant mAb 1418, or gp120
alone (Fig. 1A). The results showed that a significantly higher
level of anti-V3 mAbs (694/98D and 447-52D) bound to gp120
complexed with anti-CD4bs mAb 654D, as compared to gp120
alone (pb0.05) or to other gp120/mAb combinations (pb0.05).
The enhanced binding was observed at the different gp120+
654D concentrations tested. Similarly, we observed enhanced
binding of anti-C1 mAb EH21 to gp120+654D, as compared to
gp120 alone (pb0.05) and the other gp120/mAb combinations
(pb0.05). The enhanced binding was seen when the gp120/
mAb complexes were captured with anti-C5 Ab (Fig. 1A) or
directly coated onto the ELISA wells (data not shown). In
contrast, no enhancement was seen with the binding of anti-C5
mAb 1331A (pN0.05), indicating that only specific regions of
gp120 were affected by the anti-CD4bs mAb. These results are
consistent with previous studies showing that the anti-CD4bs
mAbs mainly enhanced the binding of mAbs to V3 and V2, but
not to C5 (Moore and Sodroski, 1996). We subsequently tested
six different anti-CD4bs mAbs for the capacity to increase the
exposure of V3 and C1. As shown in Fig. 1B, all six anti-CD4bs
mAbs increased mAb binding to the V3 and C1 regions of
gp120 (pb0.05). These results indicate that the binding of anti-
CD4bs mAbs induces conformational changes in gp120, such
that the V3 and C1 regions react better with Abs. In addition to
the gp120/anti-CD4bs mAb complexes, gp120 complexed with
anti-C2 mAb 1006-30D also had enhanced reactivity with anti-
V3 mAb 694/98D and anti-C1 mAb EH21 (pb0.05), albeit at
lower levels. However, the reactivity of this gp120/anti-C2
complex with anti-V3 mAb 447 was not altered (pN0.05), sug-
gesting the differential effects of anti-CD4bs vs. anti-C2 mAbs
on V3 reactivity. The reasons for the observed differences
between anti-CD4bs and anti-C2 mAbs are not known, but are
not likely due to differences in the mAb affinity for gp120, since
the relative affinities of the anti-CD4bs and anti-C2 mAbs tested
in this study were comparable, with the half maximal binding
values ranging from 0.003 to 0.02 μg/ml.
Immunization with gp120/anti-CD4bs mAb complexes elicits
higher titers of gp120-specific Ab response
To evaluate the effects of anti-CD4bs mAbs on Ab response
to gp120 in vivo, BALB/c mice were immunized i.p. 4 times
with gp120LAI complexed with 654-D, a human mAb to the
CD4bs. For comparison, we also immunized mice with
gp120LAI alone, gp120 mixed with an irrelevant anti-parvovirus
mAb 860-55D, or saline. We determined the kinetics of anti-
gp120 Ab production by testing sera collected a week after each
injection for Ab reactivity with the homologous gp120LAI
protein in ELISA. The data showed that mice immunized with
gp120, gp120+860-55D, or gp120+654D produced serum Ab
Fig. 1. Reactivity of mAbs to V3, C1, and C5 with gp120/mAb complexes. (A) gp120 or gp120/mAb complexes were captured on the ELISA plates by polyclonal anti-
C5 Abs and reacted with biotinylated mAbs specific for V3 (694/98D and 447/52D) or C1 (EH21). Alternatively, gp120 or the complexes were directly coated
onto ELISA plates and reacted with biotinylated mAbs specific for C5 (1331A). The gp120/mAb complexes were prepared with 1 μg/ml of recombinant gp120LAI and
2 μg/ml of mAbs to the CD4bs (654D) or C2 (1006-30D) and serially diluted by twofold. Gp120 mixed with a control mAb (1418) was also included as a control. The
x-axis shows the gp120 concentrations in each of the gp120/mAb mixtures. Relative binding of the biotinylated mAbs was determined using alkaline phosphatase-
conjugated streptavidin. Means and standard deviations were calculated from duplicate wells. Data from one of five repeated experiments are shown. ⁎pb0.05 as
compared with gp120 alone. (B) Different gp120/CD4bs mAb complexes or uncomplexed gp120 (gp120 and gp120+1418) were captured on the ELISA plates by
polyclonal anti-C5 Abs and reacted with biotinylated mAbs specific for V3 (694/98D) or C1 (EH21). The gp120/mAb complexes were prepared as described above.
The bars in each set represent the serial dilutions of the gp120/mAb mixtures as described above. ⁎pb0.05 as compared to gp120 alone at the first 2–3 dilutions tested,
except for gp120-F105 which is significant only at the first dilution.
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elicited higher and faster gp120-specific Ab responses than
immunization with gp120 or gp120+860-55D (Fig. 2A). Mice
that received gp120 alone or gp120 mixed with the irrelevant
mAb started to show detectable anti-gp120 Abs only after 3
injections, while mice immunized with gp120+654D had al-
ready relatively high amounts of Abs after the second injection.
No gp120-specific serum Abs were ever detected in mice im-
munized with adjuvant only.
To assess whether the enhancing effects could also be
mediated by other mAbs, we immunized mice with gp120
complexed with two different anti-CD4bs mAbs 654D or 559/64D, gp120 complexed with anti-V3 mAb 694/98D, gp120
mixed with an irrelevant anti-parvovirus mAb 1418, gp120
alone, or no antigen. Sera collected at 1 week after the final
immunization were tested in ELISA for the relative titers of
anti-gp120 Abs induced in the different groups of mice. Immu-
nization with gp120 complexed with the anti-CD4bs mAbs
654D or 559/64D induced higher titers of anti-gp120 Abs than
immunization with gp120 alone or gp120 mixed with an
irrelevant mAb (Fig. 2B). However, immunization with gp120
complexed with the anti-V3 mAb 694/98D did not have the
same enhancing effect. Mice immunized with adjuvant alone
did not have any detectable anti-gp120 Ab titers (Fig. 2B), and
Fig. 2. Reactivity of serum Abs frommice immunized with rgp120 or gp120–Ab complex against recombinant gp120. (A) The kinetics of serum Ab responses induced in
BALB/c mice immunized with gp120 alone, gp120 complexed with the anti-CD4bs mAb 654D, gp120 mixed with an irrelevant anti-parvovirus mAb 860-55D, or no
antigen (PBS) in the presence ofRIBI adjuvant. Serawere pooled from each group ofmice and tested at a dilution of 1:320. (B)Anti-gp120Ab titers in sera from1week after
final immunization. BALB/c mice were immunized with gp120 or gp120 combined with mAbs to CD4bs (654-D and 559/64D), V3 (694/98D), parvovirus (1418), or with
PBS. (C) Comparison of anti-gp120 titers in pooled sera from 3 different immunization experiments.⁎, pb0.05 at the designated serum dilutions. (D) Serum Ab titers to
human mAbs used to form the immune complexes. Reactivities of sera to the respective mAbs are shown as solid lines, while reactivities to keyhole limpet hemocyanin
(KLH), used as a negative control, are shown as dotted lines. For B, C and D, pooled sera were diluted 10 fold starting from 1:50. ELISAwas performed using recombinant
gp120LAI, humanmAbs, orKLHcoated directly on the plates and alkaline phosphatase-conjugated anti-mouse IgGas a secondary antibody.Alkaline phosphatase substrates
p-nitrophenyl phosphate (OD405) or PhosphaGlow chemiluminescent (cps) were used. Means and standard deviations were derived from duplicate wells.
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used as a negative control (data not shown). The enhancing
effect of anti-CD4bs mAb 654D was consistently observed in
different animals immunized in three separate experiments
(pb0.05) (Fig. 2C). For comparison, we tested Ab response to
the human mAbs used to form the immune complexes and
observed that mice immunized with the gp120/mAb complexes
(gp120+654D, gp120+559/64D, and gp120+694/98D) all
generated Ab response to the respective mAbs and the titers
were higher than that observed in mice immunized with the
uncomplexed gp120+1418 mixture (Fig. 2D). Collectively, the
results shown in Figs. 1 and 2 indicate that the binding of anti-CD4bs mAbs to gp120 influence Ab reactivity and Ab response
elicited against this antigen.
Immunization with gp120/anti-CD4bs Ab complexes elicits
gp120-specific IgG1 and IgA
To determine the Ig isotypes elicited by immunization with
gp120/anti-CD4bs mAb-complexes, we tested sera obtained after
the final immunization for gp120-specific IgG and IgA.
Mice immunized with gp120+654D or gp120+559/64D showed
100–1000× higher titers of gp120-specific IgG (end point titers of
5×106) as compared to the other groups of mice (Fig. 3A). These
Fig. 3. Ig classes induced in mice immunized with gp120 in the presence or absence of mAbs. Mice were immunized with gp120 alone, gp120 complexed with
different anti-gp120 mAbs, or PBS. For comparison, mice were also immunized with gp120 combined with anti-parvovirus mAbs (1418 or 860-55D). The results
obtained with sera from two different immunization experiments are shown in A and B. (A) Sera were collected a week after the final boost, serially diluted, and tested
for titers of gp120-specific IgG and IgA. (B) For detection of gp120-specific IgG1, IgG2a, and IgG2b, sera collected 1 week after each immunization were used and
tested at a dilution of 1:640. Gp120LAI was captured on ELISA plates coated with sheep anti-C5 antibody and reacted with diluted mouse sera. Rabbit antibodies
against different mouse Ig subtypes and subclasses and alkaline phosphatase-conjugated anti-rabbit IgG were used for detection along with alkaline phosphatase
substrates p-nitrophenyl phosphate (OD405) or PhosphaGlow chemiluminescent. Means and standard deviations were derived from duplicate wells.
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titer of 5×104), while the other groups of mice did not (Fig. 3A).
In a subsequent experiment, we evaluated the IgG subclasses
induced following immunizationwith gp120+654D as compared
to gp120 alone or gp120 mixed with an irrelevant mAb 860-55D.
Sera from 1 week after each immunization were tested for anti-
gp120 IgG1, IgG2a, and IgG2b. Mice receiving gp120+654D
produced higher levels of gp120-specific IgG1 as compared to the
other groups (Fig. 3B), indicating that Th2-like responses were
induced by the gp120/mAb complex (Stevens et al., 1988).
Similar results were obtained with sera from mice immunized
with gp120+559/64D (data not shown).
Immunization with gp120/anti-CD4bs Ab complexes elicits
higher anti-V3 Ab response
We next asked if certain regions of gp120 were preferentially
targeted by Abs elicited in mice immunized with gp120/anti-CD4bs mAb-complexes. To address this question, sera obtained
after the final immunization were tested by ELISA for their
reactivity with gp120 peptides representing the C1, C5 and V3
regions and with a gp120 core protein lacking C1, C5, V1/V2,
and V3 (Fig. 4). Enhanced reactivity against the V3 peptide was
observed with sera from mice immunized with gp120
complexed with anti-CD4bs mAbs 654D and 559/64D as
compared with the other groups. In fact, high levels of anti-V3
Abs were detected only in mice receiving gp120+654D or
gp120+559/64D, while sera from the other groups had no
significant reactivity above that seen in control mice. In con-
trast, reactivities against C1 and C5 peptides were similar or
only slightly higher in sera from mice immunized with gp120+
654D or gp120+599/64D. All groups of mice also had com-
parable serum Ab reactivity with the gp120 core. These results
demonstrate that immunization with gp120/anti-CD4bs mAb
complexes enhanced the Ab response to V3, while still eliciting
comparable Ab titers to other gp120 regions.
Fig. 4. Reactivity of serum Abs from mice immunized with rgp120 or gp120–mAb complexes with V3, C1, C5, and gp120 core. Sera collected from the final bleed
were tested by ELISA using peptides representing the V3, C1 and C5 regions of gp120 and against core gp120 protein lacking V1/V2, V3, and the N and C termini.
Peptides or core gp120 were coated on the ELISA plates and reacted with serially diluted sera. Mouse Ab binding was assessed by alkaline phosphatase-conjugated
secondary antibody to mouse IgG. Note the differences in the scales of y-axis for the right and left graphs.
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CD4bs, we next checked the sera for the presence of Abs
against the CD4bs by comparing the serum Ab binding to
gp120 in the presence or absence of sCD4 (Fig. 5). The results
demonstrate that immunization with gp120 mixed with the
irrelevant mAb 1418 induced production of Abs to the CD4bs,
as indicated by the reduced Ab reactivities in the presence of
sCD4, although the difference in reactivities in the presence
versus absence of sCD4 was not statistically significant. In
contrast, none of the other groups elicited Abs that competed
with sCD4 in the binding to gp120, suggesting that Abs to the
CD4bs were not induced to significant levels. At this point, the
epitopes in the gp120 core recognized by the sera of mice
immunized with the different gp120/mAb complexes remain
unknown. It is also unclear as to why the gp120/anti-V3 mAb
complex did not generate anti-CD4bs Abs. Further studies are
needed to investigate this issue, but a previous study reported
that some degrees of inhibition was observed when anti-CD4bs
mAbs b12 and F91 were reacted with certain gp120/anti-V3
mAb complexes (Moore and Sodroski, 1996).
Abs elicited by immunization with gp120/anti-CD4bs mAb
complexes react preferentially with the homologous V3 peptide
To assess if the anti-V3 Abs elicited in mice immunized with
the gp120/anti-CD4bs mAb complexes were able to recognize
peptides representing V3 from different HIV-1 strains, sera
collected after the last immunization were serially diluted and
tested by ELISA for their reactivity to different V3 peptides
with sequences from SF162, MN, JR-CSF, and the homologous
LAI (Fig. 6). The reactivity of sera from mice receiving gp120mixed with the irrelevant mAb 1418 was also tested for com-
parison. All groups of mice receiving different gp120/mAb
combinations had serum reactivity with each of the four V3
peptides above the level observed with the control mouse sera.
However, sera from mice immunized with gp120/mAb-
complexes (gp120+654D and gp120+559/64D) had much
higher reactivity with the homologous V3 peptide than with the
heterologous V3 peptides. In contrast, sera from mice
immunized with gp120+1418 had similar, albeit much lower,
reactivity to homologous and heterologous V3 peptides. These
results indicate that immunization with gp120/anti-CD4bs mAb
complexes generates high levels of anti-V3 Abs that preferen-
tially react with the homologous V3, although these complexes
can also induce low levels of cross-reactive anti-V3 Abs.
Serum Abs elicited by immunization with gp120/anti-CD4bs
mAb complexes potently neutralize homologous, but not
heterologous HIV-1 isolates
Next we assessed the neutralizing activity of sera from mice
immunized with gp120 complexed with the anti-CD4bs mAb
(mAb 654D), gp120 mixed with the irrelevant mAb (mAb 860-
55D), or gp120 alone. Neutralization assays with single-round
infection of different HIV-1 strains were performed in TZM-bl
cells (Choudhry et al., 2007). Serial dilutions of immune sera
obtained after the final immunization were initially tested
against HIV-1LAI expressing envelope homologous to the gp120
immunogen used for immunization (Fig. 7). Strong neutralizing
activity was found in the sera of mice immunized with the
gp120/anti-CD4bs mAb-complex (gp120+654D). At a 1:50
dilution, sera from this group were able to neutralize HIV-1LAI
Fig. 5. Detection of Abs to the CD4-binding site of gp120 in sera of mice
immunized with the gp120/Ab complexes. Serum Abs to the CD4bs was
measured by ELISA by comparing serum reactivity to gp120 in the presence or
absence of sCD4. Sera were collected after the last immunization from mice
immunized with gp120 combined with mAbs to CD4bs (654-D and 559/64D),
mAb to V3 (694/98D), or control mAb (1418), or no antigen (PBS). These sera
were serially diluted and reacted with gp120 captured on the wells in the
presence or absence of sCD4 (1 μg/ml). Means and standard deviations from
duplicate wells are shown. There is no statistical significant difference between
Ab reactivities in the presence versus absence of sCD4.
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present at a dilution of 1:250. In contrast, sera from the other
groups (gp120 and gp120+860-55D) showed no neutralizing
activity above that of control sera from mice receiving adjuvant
alone. To assess whether the neutralizing activity observed in the
serum from gp120+654D-immunized mice was mediated by
anti-V3 Abs, the serum was treated with V3 peptide or an
irrelevant control peptide prior to use in the neutralization assay
(Fig. 7B). Treatment with V3 peptide, but not with the control
peptide, significantly reduced the serum neutralizing activity
(pb0.05 at each of the 3 serum dilutions tested), indicating that
anti-V3 Abs play a major role in neutralization against this virus,
albeit Abs directed to other yet undefined epitopes may also be
present and contribute to the neutralization observed in the
serum.
We subsequently tested the ability of sera from mice im-
munized with gp120/anti-CD4bs complexes (gp120+654D and
gp120+559/64D) to neutralize other HIV-1 isolates known to
have different degrees of sensitivity to Ab-mediated neutraliza-tion, i.e. SF162 (subtype B), BX08 (subtype B), JRFL (subtype
B) and DJ263 (CRF02_AG) (Table 1). For comparison, we also
tested sera from mice immunized with gp120 complexed with
the anti-V3 mAb (gp120+694/98D), gp120 combined with an
irrelevant control Ab (1418), or no antigen. While sera from
mice immunized with gp120+654D or gp120+559/64D potent-
ly neutralize HIV-1LAI, these same sera had little or no neutral-
ization activity against the other viruses tested. Mice immunized
with gp120+694/98D showed weak or no neutralizing serum
activity against all five viruses, including the homologous LAI.
Sera from mice immunized with gp120+1418 had no neutraliz-
ing activity, similar to the control group receiving no antigen.
Taken together, these results indicate that the binding of anti-
CD4bs mAb to gp120 enhances the immunogenicity of this
antigen such that significantly higher levels of anti-gp120 Abs
are generated upon immunization with the gp120/anti-CD4bs
mAb complexes than with uncomplexed gp120 or gp120
combined with other mAbs. Notably, the high levels of Abs
elicited by these complexes are directed to the V3 region and
display potent virus-neutralizing activity, at least against the
homologous HIV-1LAI.
Discussion
This study investigates the capacity of anti-CD4bs Abs
forming immune complexes with the envelope glycoprotein
gp120 in augmenting Ab responses against HIV-1. The data
demonstrate that the interaction of anti-CD4bs mAbs with
gp120 altered the antigenic and immunogenic properties of this
antigen. When BALB/c mice were immunized with the gp120/
anti-CD4bs mAb complexes, serum anti-gp120 Ab responses
were generated with faster kinetics and to higher titers. This
finding is in agreement with very early reports showing the
ability of immune complexes to enhance Ab responses due to
their deposition on FDCs that can retain antigens for long period
of time and stimulate B cell proliferation and germinal center
formation following T cell-dependent or complement-depen-
dent CD40 activation (Gaspal et al., 2006). Immunization with
gp120 mixed with an irrelevant control mAb also induced
higher anti-gp120 Ab titers as compared to immunization with
gp120 alone, indicating that IgG may have an Fc-mediated
adjuvant activity as described earlier in the literature (Dawe
et al., 1970; Heyman, 1990; Wernersson et al., 2000; Wiersma
et al., 1989). It should be noted, however, that gp120/anti-
CD4bs mAb complexes displayed a unique property in that
these complexes enhanced Ab response against the V3 region of
gp120, without diminishing Ab response to the other gp120
regions. Indeed, high levels of serum anti-V3 Abs were detected
in animals immunized with these complexes, but not in animals
immunized with uncomplexed gp120, while all groups of ani-
mals generated comparable Ab titers to the gp120 core. Animals
immunized with the gp120/anti-V3 mAb complex also elicited a
poor anti-V3 Ab response, presumably because of the shielding
of this epitope by the mAb. These results correspond with
findings reported by us and others that anti-V3 mAbs reacted
better with gp120 bound by anti-CD4bs mAbs than with gp120
alone (Fig. 1 and Pinter et al., 1993). These findings are also
Fig. 6. Serum reactivity of mice immunized with gp120 or gp120/mAb complexes with V3 peptides of heterologous strains. Sera from the final bleed were tested by
ELISA for reactivity with different V3 peptides of heterologous strains SF162, MN, JR-CSF as compared to the homologous V3LAI peptide. Differences in the V3
sequences of these viruses are shown. V3 peptides were coated on the ELISA plates and reacted with serially diluted sera. Serum Ab binding was detected using an
alkaline phosphatase-conjugated secondary antibody to mouse IgG.
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with soluble gp120 or native envelope on HIV virions resulted
in increased reactivity of anti-V3 mAbs (Mbah et al., 2001;
Sattentau and Moore, 1991; Sattentau et al., 1993). A few other
anti-gp120 mAbs directed to V2, C1, or C2 have also been
shown to enhance the binding of some anti-V3 mAbs (Fig. 1
and Moore and Sodroski, 1996), but whether immunization
with these other gp120/mAb complexes induces more robust
Ab responses to V3 remains to be determined. The enhanced
binding of anti-V3 mAbs suggests that the V3 region is more
exposed on these complexes. Alternatively, these mAbs may
restrain V3 flexibility and make it adopt a conformation that is
well recognized by Abs.
The V3 region is known to have highly variable sequences
but it also maintains a conserved structure required for its
interaction with the chemokine receptors (Zolla-Pazner, 2005).
Abs generated to this immunogenic site also displayed different
binding and neutralizing activities, as exemplified by the two
anti-V3 mAbs tested here for reactivity with the gp120/anti-
CD4bs mAb complexes, 694/98D and 447-52D. MAb 694/98D
preferentially binds to V3LAI and neutralizes HIV-1LAI most
potently, but it also is effective against a few other neutraliza-
tion-sensitive strains of HIV-1. On the other hand, mAb 447-52D is one of the anti-V3 mAbs known to neutralize diverse
primary HIV-1 isolates, particularly among the subtype B
viruses. Both mAbs displayed enhanced reactivity with the
gp120/anti-CD4bs mAb complexes (Fig. 1), indicating that the
two distinct, albeit overlapping, V3 epitopes are accessible on
the immune complexes. Nevertheless, sera from mice immu-
nized with the gp120/anti-CD4bs mAb complexes did not
display broad cross-reactivity like mAb 447-52D (Fig. 6 and
Table 1). The sera showed enhanced binding to the V3LAI
peptide, but not to other V3 peptides. The sera also had potent
anti-V3 neutralizing activity specific for the homologous HIV-
1LAI isolate, and failed to neutralize heterologous viruses,
including the highly neutralization-sensitive SF162. These data
indicate that although the gp120/anti-CD4bs mAb complexes
elicit the production of V3-specific neutralizing Abs, the Abs
generated are skewed toward V3 epitopes that are not shared
among different HIV-1 isolates. It should be noted that this
study tested immune complexes made with gp120LAI that has a
distinctive V3 sequence due to a two-amino acid insertion
(Fig. 6). Further studies are necessary to determine whether
highly strain-specific Abs are similarly generated in response to
immune complexes made of gp120 that contains a more repre-
sentative V3 sequence. Nevertheless, other factors such as the
Table 1
Neutralization of different HIV-1 isolates by sera from mice immunized with
different gp120/mAb combinations
% Neutralization of HIV-1 isolates
LAI JRFL DJ263 BX08 SF162
Mice immunized with a
gp120+1418 b b b b b b
gp120+654D 83 35 23 b 30
gp120+559/64D 90 b 21 b 29
gp120+694/98D 26 46 27 19 b
PBS b b b b b
MAbs to V3 c
694/98D NDd 33 b ND 82
447/52D ND b b ND 71
a All mouse sera were tested at 1:50 dilution.
b Virus neutralization of b19%.
c Anti-V3 mAbs were tested at 1 μg/ml.
d Not done.
Fig. 7. Neutralization of HIV-1LAI by sera from mice immunized with gp120 or
gp120/mAb complexes. (A) Sera collected after the final immunization were
tested for neutralizing activity in the single-round infection assay with TZM-bl
cells and HIV-1LAI. Mice were immunized with gp120LAI alone, gp120LAI
mixed with CD4bs mAb 654D, or control mAb (860-55D), or no antigen (PBS)
in the presence of RIBI adjuvant. (B) Treatment of serum from gp120+654D-
immunized mice with V3 peptide or a control peptide. Serially diluted serum
was pre-incubated with V3 peptide or control peptide (180 μg/ml) or left
untreated, and tested in the neutralization assay as described in the Materials and
methods. Virus infectivity in cells treated with virus in the presence of pooled
normal mouse sera was assessed in each assay and considered as background
(0% neutralization). Data from one of two repeat experiments are shown.
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the particular anti-CD4bs mAb tested may also account for the
exquisite specificity for the serum Abs from the gp120/654
immunized mice. In addition, more boosts and longer resting
periods between injections may be necessary to elicit more
broadly reactive neutralizing Abs, since data from a previous
immunization study using recombinant gp120 proteins indicate
that neutralizing Abs against heterologous viruses are generated
only after the sixth and seventh injections following a resting
period (Haigwood et al., 1992).
Anti-CD4bs Abs induce gp120 to undergo conformational
changes, as indicated by enhanced Ab reactivity to V3 and C1
on the gp120/anti-CD4bs mAb complexes (Fig. 1). However,
only V3 immunogenicity was markedly enhanced when gp120/
anti-CD4bs complexes were used as immunogens (Fig. 4). The
C1 region in the N-terminus of gp120 did not appear to be as
immunogenic as V3 for BALB/c mice. Indeed, the levels of
anti-C1 Abs detected in the sera after immunization with gp120
or gp120/mAb combinations were relatively low, as compared
to the Ab levels against V3, whole gp120 or gp120 core.
Whether a similar repertoire of Abs is elicited by the gp120/
anti-CD4bs mAb complexes in other mouse strains and in other
species is not yet known; however, V3 has been documented tobe highly immunogenic in different species including humans.
CD4 binding to gp120 also enhances V3 reactivity (Mbah et al.,
2001; Sattentau and Moore, 1991; Sattentau et al., 1993), but
previous immunization experiments utilizing CD4-envelope
complexes did not determine if such complexes also generated
high levels of V3-specific Ab responses (Denisova et al., 1996;
Fouts et al., 2002; He et al., 2003; Kang et al., 1994). We should
note, however, that unlike CD4, the binding of anti-CD4bs Abs
to gp120 does not trigger formation of the chemokine-receptor
binding site. Anti-CD4bs Abs actually prevent gp120 from
binding the chemokine receptor and from reacting with mAbs
specific for the chemokine-receptor binding site (Raja et al.,
2003; Hioe et al., unpublished data). Hence, it is unlikely that
Abs to the chemokine-receptor site (anti-CD4i) would be
produced in response to the gp120/anti-CD4bs mAb complexes.
This is supported by our observation that gp120 reactivity of
serum Abs from mice immunized with the immune complexes
was not enhanced by soluble CD4 (Fig. 5). Nevertheless, a
previous immunization study using gp120 complexed with
mAb A32, which specifically induces the binding of chemo-
kine-receptor binding site, also did not appear to induce cross-
reactive Abs against this conserved region on gp120 (Liao et al.,
2004). Hence, it is of interest to evaluate in future studies as to
which gp120/mAb combinations will alter not only antigenicity
but also immunogenicity of the gp120 antigen.
It is reasonable to expect that Abs to the highly conserved
CD4bs should be able prevent the interaction of diverse isolates
of HIV-1 with their common CD4 receptor and provide some
protection for the infected hosts. However, except for recom-
binant IgG1 b12, the majority of anti-CD4bs mAbs identified so
far have poor or no neutralizing activities against most HIV-1
primary isolates (Hioe et al., 1997; Pantophlet et al., 2003).
Moreover, higher titers of anti-CD4bs Abs are actually found in
HIV+ subjects with rapid disease progression than in slow
progressors or long-term non-progressors (Chien et al., 2004a,
2002). Our previous studies also demonstrate that the binding of
anti-CD4bs Abs to gp120 interferes with gp120 antigen pro-
cessing and down-modulates class II MHC-restricted T cell
responses to gp120 (Chien et al., 2004a,b). These inhibitory
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mAbs, and not by mAbs to other gp120 epitopes examined so
far (Tuen et al., 2005). These effects have been initially detected
in vitro on the responses of human gp120-specific CD4 T cell
lines, and are consistent with recent in vivo observations
showing the suppression of gp120-specific lymphoproliferation
in mice receiving gp120/anti-CD4bs mAb complexes (Visciano
et al. manuscript in preparation). The data presented in this
paper also raise another possibility that anti-CD4bs Abs elicited
during HIV infection would enhance Ab responses to gp120,
but the Abs have a narrow breath of neutralization activity.
Hence, the generation of high titers of anti-CD4bs Abs, as
observed in HIV+ rapid progressors prior to any clinical signs of
AIDS, may not be beneficial to the host.
This study provides the first evidence that the use of immune
complexes can augment and direct Ab responses to a specific
neutralizing epitope on HIV-1 envelope gp120. Although the
Abs induced by gp120/anti-CD4bs mAb complexes tested here
have restricted virus-neutralizing activities, further studies
utilizing this approach may lead to identification of optimal
gp120/mAb complexes and immunization protocols that will
elicit not only higher levels of anti-gp120 Abs but also Abs
against cross-reactive neutralizing epitopes. The vaccination
strategy that focuses Ab responses toward neutralizing epitopes
on HIV envelope glycoproteins will be valuable for the pursuit
of effective Ab-based vaccines against HIV.
Materials and methods
Antigens and mAbs
The recombinant HIV-1 gp120LAI used in the study was
purchased from Progenics (Tarrytown, NY), while gp120YU-2
core protein was kindly provided by Richard Wyatt (Vaccine
Research Center, NIH). Human mAbs were gifts from Susan
Zolla-Pazner (New York University [NYU] School of Medicine,
New York, NY), Abraham Pinter (Public Health Research
Institute, UMDNJ, Newark, NJ), and James Robinson (Tulane
University, New Orleans, LA). Except for the recombinant IgG1
b12, anti-gp120 mAbs were all generated from B cells of
chronically HIV-1-infected subjects following Epstein–Barr
virus transformation and fusion with heteromyeloma. MAbs
654D, 559/68D, 1027/30D, IgG1b12, 5145A, and F105 are
directed to the CD4bs (Jeffs et al., 2001; Karwowska et al., 1992;
Kessler et al., 1997; Posner et al., 1991; Tuen et al., 2005), mAbs
694/98-D (Gorny et al., 1993) and 447/52D (Gorny et al., 1992)
recognize V3, mAb 1006-30D is directed to C2 (Nyambi et al.,
2000), mAb 1331A (Bandres et al., 1998; Hochleitner et al.,
2000) is specific for C5, and mAb EH21 recognizes the N-
terminus of gp120 (C1) (Haynes et al., 2005). MAbs 860-55D
and 1418, which recognize the parvovirus B19 VP2 antigen
(Gigler et al., 1999), were used as negative controls. Biotinylated
mAbs were prepared using EZ-link sulfo-NHS-biotin reagents
(Pierce, Rockford, IL). Gp120 peptides were obtained from
NIBSC Centre for AIDS Reagents (EU Programme EVA/AVIP)
or purchased from Macromolecular Resources (Colorado State
University, Boulder, CO), Intracel (Cambridge, MA), or SigmaGenosys (Woodlands, TX). The following peptides were used:
V3LAI/HXB2 (aa 272–291), V3SF162 (aa 272–291), V3JR–CSF (aa
272–296), V3MN (aa 272–296), six overlapping 20-mers
representing C1LAI/HXB2 (aa 1–71) and three overlapping 20-
mers representing C5LAI/HXB2 (aa 442–481). The following
reagents were obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH:
soluble human CD4 (sCD4) from Dr. Sai Iyer, HIV-1 gp120
monoclonal antibody (F105) from Drs. Marshall Posner and
Lisa Cavacini, and IgG1 b12 from Drs. Dennis Burton and
Carlos Barbas.
Ab reactivity to gp120 complexed with the anti-CD4bs mAb
Gp120 alone or gp120/mAb complexes were serially diluted
and then adsorbed directly onto ELISA plate or captured with
sheep anti-C5 Ab (Cliniqa, Fallbrook, CA). After washing,
biotinylated anti-gp120 mAbs (1 μg/ml) were added, and
detected by alkaline phosphatase-conjugated streptavidin (Invi-
trogen, Grand Island, NY) and p-nitrophenyl phosphate
(Sigma-Aldrich, Saint Louis, MO).
Immunization with gp120/mAb combinations
BALB/c mice (female, N6 weeks old from Jackson Lab, 8
mice per group), were inoculated intraperitoneally with gp120LAI
(3 μg gp120 per animal in 100 μl at two sites) alone or with mAb.
Each immune complex was prepared at molar gp120/mAb ratios
of approximately 1:3 or 1:10 by incubating gp120 with mAbs for
2 h at 37 °C. Gp120 or the immune complexes were mixed
according to the manufacturer's directions with MPL+TDM
adjuvant (Sigma-Aldrich, St Louis, MO). Animals were immu-
nized 4 times at the designated intervals. Blood was collected
1 week after each immunization; at each time point, the sera
from two animals in each group were pooled, and then stored at
−80 °C. The animal study was carried out according to the
protocol approved by the VA and NYU IACUC.
ELISA for detection of serum Abs
The levels of gp120 specific Ab in the sera were determined
using ELISA. Briefly, gp120 proteins (1 μg/ml) or peptides (1 μg/
ml) were adsorbed onto ELISA plates (Immunoblot 2HB or
Microfluor 2 Black; Thermo, Milford, MA) overnight at 4 °C.
Sera were serially diluted in RPMI containing 15% FBS and
reacted with the coated antigens for 2 h at 37 °C. Alkaline
phosphatase-conjugated anti-mouse IgG (1:1000; Sigma-Aldrich,
St Louis, MO) was used as a secondary Ab, while p-nitrophenyl
phosphate (Sigma-Aldrich, Saint Louis, MO) or PhosphaGlow™
AP substrate (KPL, Gaithersburg, MA) were used as substrates.
The optical density was read on a microplate reader (MRX
Revelation DYNEX) at 405 nm, and the chemiluminescence was
read on a VICTOR3 instrument (Perkin-Elmer). To detect Ab
response to the human mAbs or the control antigen (keyhole
limpet hemocyanin: KLH), ELISA plates were coated with
the mAbs or KLH (1 μg/ml), and reacted with diluted sera as
described above.
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Microfluor 2 Black plates (Thermo, Milford, MA) were coated
overnight at 4 °C with 1 μg/ml sheep polyclonal anti-C5 Ab
(Cliniqa, Fallbrook, CA). Gp120LAI (1μg/ml) was then added and
incubated 2 h at 37 °C. After washing, serially diluted sera were
reacted for 2 h at 37 °C.Rabbit Abs againstmouse IgA, IgG, IgG1,
IgG2a, or IgG2b (Zymed, San Francisco, CA) were then added,
and alkaline phosphatase-conjugated goat anti-rabbit IgG (Sigma-
Aldrich, Saint Louis,MO)was used as a secondaryAb, alongwith
PhosphaGlow™ AP substrate (KPL, Gaithersburg, MA).
To detect the presence of Abs to the CD4bs in the immune
sera, gp120LAI captured by sheep anti-C5 Ab (Cliniqa,
Fallbrook, CA) (1 μg/ml) was incubated with serially diluted
sera in the presence or absence of sCD4 (1 μg/ml). Alkaline
phosphatase-conjugated anti-mouse IgG (Sigma-Aldrich, Saint
Louis, MO) was then used along with p-nitrophenyl phosphate
substrate (Sigma-Aldrich, Saint Louis, MO). In parallel control
experiments, we also measured the reduction of anti-CD4bs
mAb 654D (1 to 0.03 μg/ml) binding to gp120 in the presence
of sCD4 (data not shown).
Virus neutralization assay
Serum neutralization activity was determined in a single-
cycle infectivity assay using HIV-1 isolates produced in PHA-
stimulated PBMCs and the TZM-bl target cells (Choudhry et al.,
2007). Viruses (200 TCID50) were incubated for 1 h at 37 °C in
96-well plates with diluted sera. In some experiments, the
diluted sera were pre-incubated with the V3LAI/HXB2 peptide or
an irrelevant peptide control (180 μg/ml). Freshly trypsinized
TZM-bl cells were added (104/well) to the virus–serum mixture
in the presence of DEAE (diethylaminoethyl) (Sigma-Aldrich,
Saint Louis, MO) and Indinavir (1 μM). After 48 h, Bright-Glo
(Promega, Madison, WI) reagent was added and luminescence
intensity was determined. Two anti-V3 mAbs known to have
neutralizing activity (694/98D and 447-52D) were also included
in this assay as controls.
Statistical analysis
Statistical analyses were performed using one-way ANOVA
with Dunnett's multiple comparison test for each of the concen-
trations tested in Fig. 1A or two-way ANOVAwith Bonferroni's
post-test for Figs. 1B and 7B. For two-group comparisons in
Figs. 2C and 5 unpaired t test (one-tail) was performed. These
analyses were done with GraphPad Prism 5.
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